To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease

• Status: Terminated
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers Disease. The total treatment period is 9 weeks, divided into 5 equally long sub-periods of 7 days and 4 wash-out periods of 7 days each.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Clinical diagnosis of probable Alzheimer´s Disease

• Hachinski Ischaemic score < 4

• MSE score 18 to 24

Exclusion Criteria:

• History of any clinically significant disease or dementia other than Alzheimer´s Disease

• Current major depressive disorder or other major psychiatric disorders